Epilepsy Clinical Trial
Official title:
The Impact of Mindfulness Meditation in Veterans With Epilepsy: Can Seizures and Psychiatric Comorbidities Improve
Verified date | September 2020 |
Source | Miami VA Healthcare System |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Epilepsy is one of the fourth most common neurological disorder and affects people of all
ages and about 25 % of those patients have medically intractable epilepsy. Since the
traditional pharmaceutical and surgical approach is not always effective, this study intends
to investigate a novel approach using mindfulness as adjunctive tool of treatment for
veterans with epilepsy.
This study proposes a randomized, single-blinded pilot investigative trial to assess the
effectiveness of mindfulness meditation. The measures outcomes include seizure frequency,
number of ER visits, quality of life, depression, anxiety, post traumatic stress disorder
(PTSD), sleep quality and alcohol use in patients with Epilepsy. The cohort group will be
randomized in two groups, one is the group of patients getting mindful meditation weekly
during 8 weeks compared to patients in the waiting list who have the desire to participate.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | September 2020 |
Est. primary completion date | August 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility |
Inclusion Criteria: 1. Diagnosis of epilepsy, according to the using the 2014 International League Against Epilepsy criteria 2. Adults over the age of 18 3. Willingness to participate in mindfulness meditation sessions weekly for 8 weeks 4. Being able to read at a 6th grade level. 5. Being able to understand the study, consent form, and guided instructions during mindfulness meditation. Exclusion Criteria: 1. Having an isolated diagnosis of psychogenic non-epileptic seizures. 2. Having a diagnosis of major neurocognitive disorder previously known as dementia which would make the patient unable to follow guided instructions during mindfulness meditation. |
Country | Name | City | State |
---|---|---|---|
United States | miami VAMC | Miami | Florida |
Lead Sponsor | Collaborator |
---|---|
Miami VA Healthcare System |
United States,
Acevedo BP, Pospos S, Lavretsky H. The Neural Mechanisms of Meditative Practices: Novel Approaches for Healthy Aging. Curr Behav Neurosci Rep. 2016;3(4):328-339. Epub 2016 Oct 18. Review. — View Citation
Arias AJ, Steinberg K, Banga A, Trestman RL. Systematic review of the efficacy of meditation techniques as treatments for medical illness. J Altern Complement Med. 2006 Oct;12(8):817-32. Review. — View Citation
Guidelines for epidemiologic studies on epilepsy. Commission on Epidemiology and Prognosis, International League Against Epilepsy. Epilepsia. 1993 Jul-Aug;34(4):592-6. — View Citation
Hauser WA, Annegers JF, Rocca WA. Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin Proc. 1996 Jun;71(6):576-86. Review. — View Citation
Moyer CA, Donnelly MP, Anderson JC, Valek KC, Huckaby SJ, Wiederholt DA, Doty RL, Rehlinger AS, Rice BL. Frontal electroencephalographic asymmetry associated with positive emotion is produced by very brief meditation training. Psychol Sci. 2011 Oct;22(10) — View Citation
Pascoe MC, Thompson DR, Jenkins ZM, Ski CF. Mindfulness mediates the physiological markers of stress: Systematic review and meta-analysis. J Psychiatr Res. 2017 Dec;95:156-178. doi: 10.1016/j.jpsychires.2017.08.004. Epub 2017 Aug 23. Review. — View Citation
Tang YY, Lu Q, Feng H, Tang R, Posner MI. Short-term meditation increases blood flow in anterior cingulate cortex and insula. Front Psychol. 2015 Feb 26;6:212. doi: 10.3389/fpsyg.2015.00212. eCollection 2015. — View Citation
Vezzani A, Lang B, Aronica E. Immunity and Inflammation in Epilepsy. Cold Spring Harb Perspect Med. 2015 Dec 18;6(2):a022699. doi: 10.1101/cshperspect.a022699. Review. — View Citation
Walker ER, Obolensky N, Dini S, Thompson NJ. Formative and process evaluations of a cognitive-behavioral therapy and mindfulness intervention for people with epilepsy and depression. Epilepsy Behav. 2010 Nov;19(3):239-46. doi: 10.1016/j.yebeh.2010.07.032. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in beck depression inventory I and II (BDI-II) scores over time | We will compare the scores of BDI-II at the baseline, and after week 4 and week 8 during meditation study and 4 weeks after the completion of study. The BDI-II score range is from 0 to 63 with a higher score indicating a worsening of depression. | baseline scores at the beginning of study, at the end of week 4 and week 8 during mindfulness study and a month after completing the study (at the end of week 12) | |
Other | Change in the Beck anxiety inventory (BAI) scores over time | We will compare the scores of the DAI at the baseline, then at the end of week 4 and week 8 during meditation study and 4 weeks after the completion of study. The BAI score range is from 0 to 63 with a higher score indicating a worsening anxiety. | At the beginning of mindfulness study (baseline) and then at the end of weeks 4 and 8 during mindfulness study and one month after completion of meditation sessions (post study) | |
Other | Change in the drug abuse screening test (dast-10) scores over time | We will compare the scores of the dast-10 at the baseline, then at the end of week 4 and week 8 during the meditation study and a month after the completion of the study. The dast 10 score range from 0 to 10 with a higher number indicating a worse drug addiction. | At the beginning of mindfulness study (baseline) and then at the end of weeks 4 and 8 during mindfulness study and one month after completion of meditation sessions (post study) | |
Other | Change in the Epworth Sleepiness Scale (ESS) | We will compare the score of the ESS at the baseline, then 4, 8 and 12 week after the baseline testing. The ESS score range is from 0 to 24 with a higher score indicating higher chance of dozing | At the beginning of mindfulness study (baseline) and then at the end of weeks 4 and 8 during mindfulness study and one month after completion of meditation sessions (post study) | |
Other | Change in the Alcohol use disorder identification test (AUDIT) | Score of AUDIT at the baseline, then at week 4 and week 8 during meditation study and 4 weeks after the completion of study. The AUDIT score range from 0 to more than 20 with a higher score indicating a higher use of alcohol | At the beginning of mindfulness study (baseline) and then at the end of weeks 4 and 8 during mindfulness study and one month after completion of meditation sessions (post study) | |
Other | Change of the insomnia severity index score (ISIS) | We will compare the score of ISIS at baseline, then at week 4 and week 8 during meditation study and 4 weeks after the completion of the study. The ISIS score range is from 0 to 28 with a higher score indicating higher severity of insomnia | At the beginning of mindfulness study (baseline) and then at the end of weeks 4 and 8 during mindfulness study and one month after completion of meditation sessions (post study) | |
Other | Change of the patients health questionnaire (PHQ-9) score | Score of PHQ questionnaire at the baseline, then at week 4 and week 8 during meditation study and 4 weeks after the completion of study. The PHQ-9 score range is from 0 to 27 with a higher score indicating a more severe depression. | At the beginning of mindfulness study (baseline) and then at the end of weeks 4 and 8 during mindfulness study and one month after completion of meditation sessions (post study) | |
Other | Change of the PCL-5 scores | The PCL- 5 is a 20-item self report measure that assesses the 20 DSM-5 symptoms of the PTSD .We will compare the scores of the PCL-5 at the baseline, then at the end of week 4 and week 8 during the meditation study and 4 weeks after the completion of the study. PCL for DSM-IV suggests that a 5-10 point change represents reliable change (i.e., change not due to chance) and a 10-20 point change represents clinically significant change. | At the beginning of mindfulness study (baseline) and then at the end of weeks 4 and 8 during mindfulness study and one month after completion of meditation sessions (post study) | |
Primary | Change in number of seizures over time | Total number of seizures per 4 week periods will be compared over time. | Number of seizures in 4 weeks (baseline) prior to beginning the mindfulness study and then week 4, 8 and 12 from the begining of the study. | |
Secondary | Change in number of Emergency room (ER) visits | Number of ER visits during 3 months (baseline) prior to meditation study compared with number of ER visits during three months after the completion of meditation. | At the beginning of study ( will iclude number of ER visit 3 month prior to enrollment in study. Then at week 12 and 3 months after completing the study. | |
Secondary | Change in quality of life in epilepsy questionnaire (QOLIE-31) scores over time | Score of QOLIE - 31 at the baseline, then at week 4 and week 8 during meditation study and 4 weeks after the completion of study. The QoLIE-31 score range is from 0 to 100 with a higher score indicating a better outcome for quality of life. | At the beginning of mindfulness study (baseline) and then at the end of weeks 4 and 8 during mindfulness study and one month after completion of meditation sessions (post study) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04595513 -
Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants
|
Phase 1/Phase 2 | |
Completed |
NCT02909387 -
Adapting Project UPLIFT for Blacks in Georgia
|
N/A | |
Completed |
NCT05552924 -
Self Acupressure on Fatigue and Sleep Quality in Epilepsy Patients
|
N/A | |
Terminated |
NCT01668654 -
Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS
|
Phase 3 | |
Not yet recruiting |
NCT05068323 -
Impact of Interictal Epileptiform Activity on Some Cognitive Domains in Newly Diagnosed Epileptic Patients
|
N/A | |
Completed |
NCT03994718 -
Creative Arts II Study
|
N/A | |
Recruiting |
NCT04076449 -
Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
|
||
Completed |
NCT00782249 -
Trial Comparing Different Stimulation Paradigms in Patients Treated With Vagus Nerve Stimulation for Refractory Epilepsy
|
N/A | |
Completed |
NCT03683381 -
App-based Intervention for Treating Insomnia Among Patients With Epilepsy
|
N/A | |
Recruiting |
NCT05101161 -
Neurofeedback Using Implanted Deep Brain Stimulation Electrodes
|
N/A | |
Active, not recruiting |
NCT06034353 -
Impact of Pharmacist-led Cognitive Behavioral Intervention on Adherence and Quality of Life of Epileptic Patients
|
N/A | |
Recruiting |
NCT05769933 -
Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
|
||
Not yet recruiting |
NCT06408428 -
Glioma Intraoperative MicroElectroCorticoGraphy
|
N/A | |
Not yet recruiting |
NCT05559060 -
Comorbidities of Epilepsy(Cognitive and Psychiatric Dysfunction)
|
||
Completed |
NCT02646631 -
Behavioral and Educational Tools to Improve Epilepsy Care
|
N/A | |
Completed |
NCT02952456 -
Phenomenological Approach of Epilepsy in Patients With Epilepsy
|
||
Completed |
NCT02977208 -
Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use
|
Phase 4 | |
Recruiting |
NCT02539134 -
TAK-935 Multiple Rising Dose Study in Healthy Participants
|
Phase 1 | |
Completed |
NCT02491073 -
Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)
|
N/A | |
Terminated |
NCT02757547 -
Transcranial Magnetic Stimulation for Epilepsy
|
N/A |